Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 2/2019

01-02-2019 | Health Services Research and Global Oncology

A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Survival of Patients with Initially Diagnosed Metastatic Esophageal Cancer: A SEER-Based Study

Authors: Xin Tang, MD, Xiaojuan Zhou, MD, Yanying Li, MD, Xue Tian, MD, Yongsheng Wang, MD, PhD, Meijuan Huang, MD, PhD, Li Ren, MD, Lin Zhou, MD, PhD, Zhenyu Ding, MD, PhD, Jiang Zhu, MD, Yong Xu, MD, Feng Peng, MD, PhD, Jin Wang, MD, You Lu, MD, Youling Gong, MD, PhD

Published in: Annals of Surgical Oncology | Issue 2/2019

Login to get access

Abstract

Background

Metastatic esophageal cancer (mEC) is the end stage of esophageal cancer. We aimed to construct a predictive model predicting the cancer-specific survival (CSS) of mEC patients.

Methods

Data from 1917 patients with initially diagnosed mEC were extracted from the Surveillance, Epidemiology, and End Results database between 2010 and 2015. Patients were randomly divided into the training and validation cohorts (7:3). Cox regression was conducted to select the predictors of CSS. The validation of the nomogram was performed using concordance index (C-index), calibration curves, and decision curve analyses (DCAs).

Results

Cancer-specific death occurred in 1559/1917 (81.3%) cases. Multivariate Cox regression indicated that factors including age, sex, grade at diagnosis, number of metastatic organs at diagnosis, pathological type, local treatment, and chemotherapy were independent predictors of CSS. Based on these factors, a predictive model was built and virtualized by nomogram. The C-index of the nomogram was 0.762. The calibration curves showed good consistency of CSS between the actual observation and the nomogram prediction, and the DCA showed great clinical usefulness of the nomogram. A risk classification system was built that could perfectly classify mEC patients into three risk groups. In the total cohort, the median CSS of patients in the low-, intermediate- and high-risk groups was 11.0 months (95% confidence interval [CI] 10.1–11.9), 8.0 months (95% CI 7.3–8.7), and 2.0 months (95% CI 1.8–2.2), respectively.

Conclusions

We constructed a nomogram and a corresponding risk classification system predicting the CSS of patients with initially diagnosed mEC. These tools can assist in patient counseling and guiding treatment decision making.
Literature
1.
2.
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRefPubMed
3.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMed
4.
Enzinger PC, Ilson DH, Kelsen DP. Chemotherapy in esophageal cancer. Semin Oncol. 1999;26:12–20.PubMed
5.
Forde PM, Kelly RJ. Chemotherapeutic and targeted strategies for locally advanced and metastatic esophageal cancer. J Thorac Oncol. 2013;8:673–84.CrossRefPubMed
6.
Wu SG, Xie WH, Zhang ZQ, et al. Surgery combined with radiotherapy improved survival in metastatic esophageal cancer in a surveillance epidemiology and end results population-based study. Sci Rep. 2016;6:28280.CrossRefPubMedPubMedCentral
7.
8.
Mohamed A, El-Rayes B, Khuri FR, Saba NF. Targeted therapies in metastatic esophageal cancer: advances over the past decade. Crit Rev Oncol Hematol. 2014;91:186–96.CrossRefPubMed
9.
10.
van den Boorn H, Engelhardt E, van Kleef J, et al. Prediction models for patients with esophageal or gastric cancer: a systematic review and meta-analysis. PloS One. 2018;13:e0192310.CrossRefPubMedPubMedCentral
11.
Jung HA, Adenis A, Lee J, et al. Nomogram to predict treatment outcome of fluoropyrimidine/platinum-based chemotherapy in metastatic esophageal squamous cell carcinoma. Cancer Res Treat. 2013;45:285–294.CrossRefPubMedPubMedCentral
12.
Shiozaki H, Slack RS, Chen HC, et al. Metastatic gastroesophageal adenocarcinoma patients treated with systemic therapy followed by consolidative local therapy: a nomogram associated with long-term survivors. Oncology. 2016;91:55–60.CrossRefPubMed
13.
Chen Y, Liu Y, Cheng X, Ke S, Shi W. Optimal timing of early versus delayed radiotherapy for inoperable stage IV esophageal cancer. Int J Radiat Oncol Biol Phys. 2017;99:E140–E1.CrossRef
14.
15.
Blank S, Lordick F, Dobritz M, et al. A reliable risk score for stage IV esophagogastric cancer. Eur J Surg Oncol. 2013;39:823–30.CrossRefPubMed
16.
Wang J, Suri JS, Allen PK, et al. Factors predictive of improved outcomes with multimodality local therapy after palliative chemotherapy for stage IV esophageal cancer. Am J Clin Oncol. 2016; 39:228–35.CrossRefPubMed
17.
De B, Rhome R, Doucette J, Buckstein M. Upfront esophageal radiation and chemotherapy is associated with improved overall survival compared to chemotherapy alone for metastatic esophageal cancer. Int J Radiat Oncol Biol Phys. 2017;99:E143.CrossRef
18.
Moreno A, Zhang N, Giordano S, et al. Comparative effectiveness of chemotherapy alone versus chemotherapy and radiation therapy for patients with stage IV esophageal cancer. Int J Radiat Oncol Biol Phys. 2017; 99:E172–E3.CrossRef
19.
20.
Bleiberg H, Conroy T, Paillot B, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer. 1997;33:1216–20.CrossRefPubMed
21.
Muhr-Wilkenshoff F, Hinkelbein W, Ohnesorge I, Wolf KJ, Riecken E-O, Zeitz M, Scherubl H. A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma. Int J Colorectal Dis. 2003;18:330–4.PubMed
22.
Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004;15:955–9.CrossRefPubMed
23.
Albertsson M, Johansson B, Friesland S, Kadar L, Letocha H, Frykholm G, et al. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. Med Oncol. 2007;24:407–12.CrossRefPubMed
24.
Al-Batran SE, Ajani JA. Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer. 2010;116:2511–8.PubMed
25.
Mohammad NH, ter Veer E, Ngai L, Mali R, van Oijen MG, van Laarhoven HW. Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy. A systematic literature review and meta-analysis. Cancer Metastasis Rev. 2015;34:429–41.
26.
Guttmann DM, Mitra N, Bekelman J, Metz JM, Plastaras J, Feng W, et al. Improved overall survival with aggressive primary tumor radiotherapy for patients with metastatic esophageal cancer. J Thorac Oncol. 2017;12:1131–42.CrossRefPubMed
27.
Hingorani M, Dixit S, Johnson M, et al. Palliative radiotherapy in the presence of well-controlled metastatic disease after initial chemotherapy may prolong survival in patients with metastatic esophageal and gastric cancer. Cancer Res Treat. 2015;47:706–717.CrossRefPubMedPubMedCentral
28.
Li T, Lv J, Li F, et al. Prospective randomized phase 2 study of concurrent chemoradiation therapy (CCRT) versus chemotherapy alone in stage IV esophageal squamous cell carcinoma (ESCC). Int J Radiat Oncol Biol Phys. 2016;96:S1.CrossRef
Metadata
Title
A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Survival of Patients with Initially Diagnosed Metastatic Esophageal Cancer: A SEER-Based Study
Authors
Xin Tang, MD
Xiaojuan Zhou, MD
Yanying Li, MD
Xue Tian, MD
Yongsheng Wang, MD, PhD
Meijuan Huang, MD, PhD
Li Ren, MD
Lin Zhou, MD, PhD
Zhenyu Ding, MD, PhD
Jiang Zhu, MD
Yong Xu, MD
Feng Peng, MD, PhD
Jin Wang, MD
You Lu, MD
Youling Gong, MD, PhD
Publication date
01-02-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 2/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6929-0

Other articles of this Issue 2/2019

Annals of Surgical Oncology 2/2019 Go to the issue

Hepatobiliary Tumors

Higher Tumor Burden Neutralizes Negative Margin Status in Hepatectomy for Colorectal Cancer Liver Metastasis

Endocrine Tumors

Management of Regional Lymph Nodes in Patients with Merkel Cell Carcinoma Following a Positive Sentinel Node Biopsy: Less May be More, But is Either Enough?

Urologic Oncology

The Value of 99mTc-PSMA SPECT/CT-Guided Surgery for Identifying and Locating Lymph Node Metastasis in Prostate Cancer Patients

Translational Research and Biomarkers

Epigenetic Status of CDO1 Gene May Reflect Chemosensitivity in Colon Cancer with Postoperative Adjuvant Chemotherapy

Breast Oncology

The Role of the Neo-Bioscore Staging System in Guiding the Optimal Strategies for Regional Nodal Irradiation Following Neoadjuvant Treatment in Breast Cancer Patients with cN1 and ypN0–1

Hepatobiliary Tumors

Perioperative and Long-Term Outcomes of Laparoscopic Versus Open Lymphadenectomy for Biliary Tumors: A Propensity-Score-Based, Case-Matched Analysis